Assessment of COPD Therapy From the Physicians Perspective Using Tiotropium as an Example
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 试验地点
- 352
- 主要终点
- Success of Treatment With Tiotropium According to Physician's Assessment
研究概览
简要总结
Documentation of successful therapy with tiotropium (Spiriva Respimat; Spiriva (tiotropium 18 mcg capsules)) in COPD patients requiring long-acting bronchodilators: description of the most important outcome parameters according to the physicians assessment to determine the success of therapy. Such data are not yet available.
Also collection of physicians assessments and patients assessments of efficacy and tolerability of Spiriva Respimat, Spiriva (tiotropium 18 mcg capsules).
详细描述
Study Design:
observational
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Success of Treatment With Tiotropium According to Physician's Assessment
时间窗: 6 - 12 weeks
Evaluation of important outcome parameters (pulmonary function, dyspnoe, health-related quality of life, exercise capacity, prevention of exacerbations) which were used for the physician´s decision to assess the treatment as successful
Assessment of Efficacy According to Physician
时间窗: 6 - 12 weeks
Physician's assessment of efficacy within categories (positive/ negative), concurrent proportion of positive efficacy assessments by both physician and patient was determined
Assessment of Tolerability According to Physician
时间窗: 6 - 12 weeks
Physician's assessment of tolerability (positve/ negative), concurrent proportion of positive efficacy assessments by both physician and patient was determined
Assessment of Efficacy According to Patient
时间窗: 6 - 12 weeks
patient-reported assessment within categories (Very good, good, satisfactory, less satisfactory, unsatisfactory, missing)
Assessment of Tolerability According to Patient
时间窗: 6 - 12 weeks
Patient-reported assessment within categories (Very good, good, satisfactory, less satisfactory, unsatisfactory, missing)
次要结局
- Physician's Global Evaluation at Visit 1(0 weeks)
- Physician's Global Evaluation at Visit 2(after 6 - 12 weeks)